Estimating individualized treatment effects from randomized controlled trials: a simulation study to compare risk-based approaches

被引:7
作者
Rekkas, Alexandros [1 ]
Rijnbeek, Peter R. [1 ]
Kent, David M. [2 ]
Steyerberg, Ewout W. [3 ]
van Klaveren, David [4 ]
机构
[1] Erasmus MC, Dept Med Informat, POB 2040, NL-3000 CA Rotterdam, Netherlands
[2] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Predict Analyt & Comparat Effectiveness Ctr, Boston, MA USA
[3] Leiden Univ, Dept Biomed Data Sci, Med Ctr, Leiden, Netherlands
[4] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands
基金
欧盟地平线“2020”;
关键词
Treatment effect heterogeneity; Absolute benefit; Prediction models; OPTIMAL TREATMENT REGIMES; CLINICAL-TRIALS; DECISION-MAKING; STRATIFICATION; HETEROGENEITY; VALIDATION; MODELS;
D O I
10.1186/s12874-023-01889-6
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Baseline outcome risk can be an important determinant of absolute treatment benefit and has been used in guidelines for "personalizing" medical decisions. We compared easily applicable risk-based methods for optimal prediction of individualized treatment effects. Methods We simulated RCT data using diverse assumptions for the average treatment effect, a baseline prognostic index of risk, the shape of its interaction with treatment (none, linear, quadratic or non-monotonic), and the magnitude of treatment-related harms (none or constant independent of the prognostic index). We predicted absolute benefit using: models with a constant relative treatment effect; stratification in quarters of the prognostic index; models including a linear interaction of treatment with the prognostic index; models including an interaction of treatment with a restricted cubic spline transformation of the prognostic index; an adaptive approach using Akaike's Information Criterion. We evaluated predictive performance using root mean squared error and measures of discrimination and calibration for benefit. Results The linear-interaction model displayed optimal or close-to-optimal performance across many simulation scenarios with moderate sample size (N = 4,250; similar to 785 events). The restricted cubic splines model was optimal for strong non-linear deviations from a constant treatment effect, particularly when sample size was larger (N = 17,000). The adaptive approach also required larger sample sizes. These findings were illustrated in the GUSTO-I trial. Conclusions An interaction between baseline risk and treatment assignment should be considered to improve treatment effect predictions.
引用
收藏
页数:12
相关论文
共 38 条
[1]   Endogenous Stratification in Randomized Experiments [J].
Abadie, Alberto ;
Chingos, Matthew M. ;
West, Martin R. .
REVIEW OF ECONOMICS AND STATISTICS, 2018, 100 (04) :567-580
[2]   GENERALIZED RANDOM FORESTS [J].
Athey, Susan ;
Tibshirani, Julie ;
Wager, Stefan .
ANNALS OF STATISTICS, 2019, 47 (02) :1148-1178
[3]   Recursive partitioning for heterogeneous causal effects [J].
Athey, Susan ;
Imbens, Guido .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (27) :7353-7360
[4]   The Integrated Calibration Index (ICI) and related metrics for quantifying the calibration of logistic regression models [J].
Austin, Peter C. ;
Steyerberg, Ewout W. .
STATISTICS IN MEDICINE, 2019, 38 (21) :4051-4065
[5]   Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials [J].
Basu, Sanjay ;
Sussman, Jeremy B. ;
Rigdon, Joseph ;
Steimle, Lauren ;
Denton, Brian T. ;
Hayward, Rodney A. .
PLOS MEDICINE, 2017, 14 (10)
[6]   A BAYESIAN APPROACH TO SUBGROUP IDENTIFICATION [J].
Berger, James O. ;
Wang, Xiaojing ;
Shen, Lei .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2014, 24 (01) :110-129
[7]   Using Internally Developed Risk Models to Assess Heterogeneity in Treatment Effects in Clinical Trials [J].
Burke, James F. ;
Hayward, Rodney A. ;
Nelson, Jason P. ;
Kent, David M. .
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2014, 7 (01) :163-169
[8]   Analysis of randomized comparative clinical trial data for personalized treatment selections [J].
Cai, Tianxi ;
Tian, Lu ;
Wong, Peggy H. ;
Wei, L. J. .
BIOSTATISTICS, 2011, 12 (02) :270-282
[9]   Selection of thrombolytic therapy for individual patients: Development of a clinical model [J].
Califf, RM ;
Woodlief, LH ;
Harrell, FE ;
Lee, KL ;
White, HD ;
Guerci, A ;
Barbash, GI ;
Simes, RJ ;
Weaver, WDD ;
Simoons, ML ;
Topol, EJ .
AMERICAN HEART JOURNAL, 1997, 133 (06) :630-639
[10]   Treatment selections using risk-benefit profiles based on data from comparative randomized clinical trials with multiple endpoints [J].
Claggett, Brian ;
Tian, Lu ;
Castagno, Davide ;
Wei, Lee-Jen .
BIOSTATISTICS, 2015, 16 (01) :60-72